Booster dose evaluation	BNT162b2 (N = 11)	mRNA-1273 (N = 12)	ChAdOx1/mRNA (N = 5)	Ad26.COV2.S/mRNA (N = 6)	(N = 34)
Sex
Male	5 (45.5%)	5 (41.7%)	1 (20.0%)	2 (33.3%)	13 (38.2%)
Female	6 (54.5%)	7 (58.3%)	4 (80.0%)	4 (66.7%)	21 (61.8%)
Age (years)
Median [min, max]	55.0 [22.0, 64.0]	54.5 [48.0, 62.0]	55.0 [31.0, 60.0]	27.0 [23.0, 34.0]	54.0 [22.0, 64.0]
Days from 2nd vaccine to booster vaccine
Median [min, max]	190 [146, 273]	169 [161, 204]	163 [160, 189]	161** [128,169]	170 [128, 273]
Days from booster vaccine to Xc study visit
Median [min, max]	28.0 [21.0, 75.0]	29.5 [22.0, 45.0]	26.0 [21.0, 30.0]	25.0 [15.0, 41.0]	27.5 [15.0, 75.0]

**Days from 1st vaccine to booster vaccine.